Frontiers in Hematology

Original Research

Published on 26 Dec 2024

Unique target binding by the C-terminal region of FHR1 provides a new perception of aHUS pathology

Luce Perie
Selina Stippa
Christoph Saffer
Andrea Hartmann
Mathias Mörgelin
Svante L. H. Zipfel
Marc Thilo Figge
Thorsten Wiech
Christine Skerka
Peter F. Zipfel

Frontiers in Hematology

doi 10.3389/frhem.2024.1469176

1,949 views
2 citations

Mini Review

Published on 24 Dec 2024

Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms

Joshua W. Bliss
Spencer Krichevsky
Joseph Scandura
Ghaith Abu-Zeinah

Frontiers in Hematology

doi 10.3389/frhem.2024.1504327

2,176 views

Case Report

Published on 17 Dec 2024

A patient with concurrent EBV-negative diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case report

Monika A. Satoskar
Matthew R. Lordo
Daniel M. Jones
Nicholas B. Nowacki
Jonathan E. Brammer
John C. Reneau
Timothy J. Voorhees

Frontiers in Hematology

doi 10.3389/frhem.2024.1463487

1,698 views

Case Report

Published on 12 Dec 2024

Ruxolitinib and pegylated interferon in Chronic Neutrophilic Leukemia due to a pathogenic CSF3R germline variant: a case report

Selene Grano
Valentina Bonuomo
Diana Carli
Veronica Peri
Loredana Farinasso
Ugo Ramenghi
Daniela Cilloni
Carmen Fava

Frontiers in Hematology

doi 10.3389/frhem.2024.1508463

1,468 views

Case Report

Published on 09 Dec 2024

Case report: Vitamin B12 deficiency-associated hemolytic anemia

Chiranjeevi Sainatham
Paul Stendahl Dy
Sharanya Kaushik
Jayanth Reddy Tallapalli
Viral Patel
Vishal Jindal
Sonal Paul

Frontiers in Hematology

doi 10.3389/frhem.2024.1446241

8,589 views
3 citations

Study Protocol

Published on 06 Dec 2024

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)

Theo Leitner
Evgenii Shumilov
Christina Schwitlick
Raphael Koch
Franziska Hamm
Marion Högner
Florian Bassermann
Katja Weisel
Hermann Einsele
Martin Kortüm

Frontiers in Hematology

doi 10.3389/frhem.2024.1436845

2,324 views

Original Research

Published on 05 Dec 2024

Prevalence of measurable residual disease in patients with refractory/relapsed multiple myeloma who reached complete response: a cross-sectional multicentric study

Manuel Neves
Rita Gerivaz
Graça Esteves
Rui Bergantim
Gisela Ferreira
Henrique Coelho
Celina Afonso
Delfim Duarte
Anabela Neves
Helena Matos Silva

Frontiers in Hematology

doi 10.3389/frhem.2024.1480120

1,883 views

Review

Published on 03 Dec 2024

Delineation of erythropoietic intermediates by flow cytometry

Kathleen E. McGrath

Frontiers in Hematology

doi 10.3389/frhem.2024.1496916

4,398 views
1 citation

Original Research

Published on 02 Dec 2024

Rare cell-based liquid biopsy for improved measurement of low-grade chronic inflammation

Stefan Schreier
Prapaphan Budchart
Suparerk Borwornpinyo
Panuwat Lertsithichai
Wannapong Triampo

Frontiers in Hematology

doi 10.3389/frhem.2024.1472609

1,502 views

Original Research

Published on 26 Nov 2024

Exploring the regenerative capacity of the spleen following irradiation

Christie T. M. Short
Helen C. O’Neill
Jonathan K. H. Tan

Frontiers in Hematology

doi 10.3389/frhem.2024.1396672

2,117 views

Original Research

Published on 22 Nov 2024

Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemia

Somedeb Ball
Najla H. Al Ali
Akriti G. Jain
Luis E. Aguirre
Seongseok Yun
Onyee Chan
Zhuoer Xie
David A. Sallman
Jeffrey Lancet
Eric Padron

Frontiers in Hematology

doi 10.3389/frhem.2024.1492680

1,528 views

Case Report

Published on 15 Nov 2024

Late onset pancytopenia post chimeric antigen receptor T cell therapy triggered by a COVID-19 vaccination: a case report

Nicola Maciocia
Dean Spencer
Paul Maciocia
Anna Childerhouse
Maeve O’Reilly
Elspeth Payne
Claire Roddie

Frontiers in Hematology

doi 10.3389/frhem.2024.1435584

2,335 views

Case Report

Published on 13 Nov 2024

Case report: VEXAS syndrome and literature review

Can Jones
Stanislav Ivanov
Pablo Ferraro
Souhad Younes
Hugo Fernandez

Frontiers in Hematology

doi 10.3389/frhem.2024.1480436

2,482 views
2 citations

Review

Published on 29 Oct 2024

Early T-cell precursor acute lymphoblastic leukemia: diagnostic pitfalls, genomic alteration, novel therapeutics, and minimal residual disease monitoring

Binsah George
Kok Hoe Chan
Adan Rios

Frontiers in Hematology

doi 10.3389/frhem.2024.1463410

9,524 views
2 citations

Editorial

Published on 18 Oct 2024

Editorial: Editors’ showcase: red cells, iron and erythropoiesis

Anna Rita Migliaccio

Frontiers in Hematology

doi 10.3389/frhem.2024.1457513

1,173 views

Perspective

Published on 18 Oct 2024

The CHIP-clinic as the catalyst of preventive medicine

Hans Carl Hasselbalch
Vibe Skov
Lasse Kjaer
Trine Alma Knudsen
Christina Schjellerup Eickhardt-Dalbøge
Christina Ellervik
Sabrina Cordua
Anders Lindholm Sørensen
Sarah Friis Christensen
Marie Hvelplund Kristiansen

Frontiers in Hematology

doi 10.3389/frhem.2024.1459154

2,969 views
2 citations

Review

Published on 07 Oct 2024

Clonal evolution: a landmark of MPN evolution

Nabih Maslah
Stephane Giraudier
Bruno Cassinat
Jean-Jacques Kiladjian

Frontiers in Hematology

doi 10.3389/frhem.2024.1473920

2,852 views

Review

Published on 27 Sep 2024

Recent advancements in gene therapy for sickle cell disease and β-thalassemia

Lushen Li
Pankaj K. Mandal

Frontiers in Hematology

doi 10.3389/frhem.2024.1468952

19,146 views
9 citations

Review

Published on 25 Sep 2024

Dissecting dormancy and quiescence in hematopoietic stem cells

Liliia Ibneeva
Tatyana Grinenko

Frontiers in Hematology

doi 10.3389/frhem.2024.1401713

4,314 views
3 citations

Original Research

Published on 11 Sep 2024

Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation

Amalia Domingo-González
Rafael Alonso Fernández
Ana Jiménez
Teresa De Soto Álvarez
Ana Lerma-Verdejo
Virginia Pradillo
Gonzalo Benzo Callejo
Jose Sánchez-Pina
Elena Landete
Alberto Velasco-Valdazo

Frontiers in Hematology

doi 10.3389/frhem.2024.1438233

1,683 views

Editorial

Published on 29 Aug 2024

Editorial: Rising stars in hematopoiesis and stem cells 2023

Marcus O. Muench
Kristbjorn Orri Gudmundsson

Frontiers in Hematology

doi 10.3389/frhem.2024.1477997

1,560 views

Perspective

Published on 27 Aug 2024

Sickle cell disease: a comparative perspective on global and national initiatives

Alok Kumar
Sudip Bhattacharya

Frontiers in Hematology

doi 10.3389/frhem.2024.1457158

14,355 views
14 citations

Editorial

Published on 14 Aug 2024

Editorial: Glycobiology in hematology: a promising avenue for cancer diagnostics and therapeutics

Tao Zhang
Valerie R. Wiersma

Frontiers in Hematology

doi 10.3389/frhem.2024.1465473

1,480 views

Review

Published on 09 Aug 2024

The nexus between Helicobacter pylori infection and anemia—a systematic review

Sankeerth Kumar Motupalli
Terry L. Oroszi

Frontiers in Hematology

doi 10.3389/frhem.2024.1423494

15,108 views
4 citations

178 Publications

volumes

Volume 3 - 2024

Unique target binding by the C-terminal region of FHR1 provides a new perception of aHUS pathology

Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasms

A patient with concurrent EBV-negative diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case report

Ruxolitinib and pegylated interferon in Chronic Neutrophilic Leukemia due to a pathogenic CSF3R germline variant: a case report

Case report: Vitamin B12 deficiency-associated hemolytic anemia

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)

Prevalence of measurable residual disease in patients with refractory/relapsed multiple myeloma who reached complete response: a cross-sectional multicentric study

Delineation of erythropoietic intermediates by flow cytometry

Rare cell-based liquid biopsy for improved measurement of low-grade chronic inflammation

Exploring the regenerative capacity of the spleen following irradiation

Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemia

Late onset pancytopenia post chimeric antigen receptor T cell therapy triggered by a COVID-19 vaccination: a case report

Case report: VEXAS syndrome and literature review

Early T-cell precursor acute lymphoblastic leukemia: diagnostic pitfalls, genomic alteration, novel therapeutics, and minimal residual disease monitoring

Editorial: Editors’ showcase: red cells, iron and erythropoiesis

The CHIP-clinic as the catalyst of preventive medicine

Clonal evolution: a landmark of MPN evolution

Recent advancements in gene therapy for sickle cell disease and β-thalassemia

Dissecting dormancy and quiescence in hematopoietic stem cells

Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation

Editorial: Rising stars in hematopoiesis and stem cells 2023

Sickle cell disease: a comparative perspective on global and national initiatives

Editorial: Glycobiology in hematology: a promising avenue for cancer diagnostics and therapeutics

The nexus between Helicobacter pylori infection and anemia—a systematic review